UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

S806 Mirikizumab-Induced Transcriptome Changes in Patient Biopsies at Week 12 Are Maintained Through Week 52 in Patients With Ulcerative Colitis

The American journal of gastroenterology, 2021-10, Vol.116 (1), p.S374-S375

2021

Volltextzugriff (PDF)

Integrated analysis of global mRNA and protein expression data in HEK293 cells overexpressing PRL-1

PloS one, 2013-09, Vol.8 (9), p.e72977

2013

Volltextzugriff (PDF)

Generation and Characterization of Mirikizumab, a Humanized Monoclonal Antibody Targeting the p19 Subunit of IL-23

The Journal of pharmacology and experimental therapeutics, 2023-11, Vol.387 (2), p.180-187

2023

Volltextzugriff (PDF)

569 A TRANSCRIPTOME-DEPENDENT PROGNOSTIC MODEL OF RESPONSE IN PATIENTS WITH ULCERATIVE COLITIS

Gastroenterology (New York, N.Y. 1943), 2023-05, Vol.164 (6), p.S-101-S-102

2023

Volltextzugriff (PDF)

The Formation of Amphotericin B Ion Channels in Lipid Bilayers

Biochemistry (Easton), 1997-04, Vol.36 (16), p.4959-4968

1997

Volltextzugriff (PDF)

Deconvolution of monocyte responses in inflammatory bowel disease reveals an IL-1 cytokine network that regulates IL-23 in genetic and acquired IL-10 resistance

Gut, 2021-06, Vol.70 (6), p.1023-1036

2021

Volltextzugriff (PDF)

Tu1467: MIRIKIZUMAB-INDUCED UPREGULATION OF COLONIC TRANSCRIPTS CORRELATES WITH IMPROVEMENTS IN STOOL FREQUENCY IN A PHASE 2 STUDY OF PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS

Gastroenterology (New York, N.Y. 1943), 2022-05, Vol.162 (7), p.S-973-S-974

2022

Volltextzugriff (PDF)

Sa1125 GENE EXPRESSION (GE) VALUES IN A PHASE 2 TRIAL OF MIRIKIZUMAB IN ULCERATIVE COLITIS (UC) CORRELATE BETTER WITH HISTOPATHOLOGY (HP) THAN ENDOSCOPY (EN) AND MAYO SCORES

Gastroenterology (New York, N.Y. 1943), 2020-05, Vol.158 (6), p.S-284-S-285

2020

Volltextzugriff (PDF)

Tu1854 MIRIKIZUMAB REGULATES GENES INVOLVED IN ANTI-TNF RESISTANCE AND ULCERATIVE COLITIS DISEASE ACTIVITY

Gastroenterology (New York, N.Y. 1943), 2020-05, Vol.158 (6), p.S-1189-S-1189

2020

Volltextzugriff (PDF)

Mirikizumab-Induced Transcriptome Changes in Ulcerative Colitis Patient Biopsies at Week 12 Are Maintained Through Week 52

Clinical and translational gastroenterology, 2023-11, Vol.14 (11), p.e00630-e00630

2023

Volltextzugriff (PDF)

Mirikizumab Regulates Genes Involved in Ulcerative Colitis Disease Activity and Anti-TNF Resistance: Results From a Phase 2 Study

Clinical and translational gastroenterology, 2023-07, Vol.14 (7), p.e00578-e00578

2023

Volltextzugriff (PDF)

Prediction of in vivo clearance and associated variability of CYP2C19 substrates by genotypes in populations utilizing a pharmacogenetics-based mechanistic model

Drug metabolism and disposition, 2015-06, Vol.43 (6), p.870-883

2015

Volltextzugriff (PDF)

Exploiting chemical diversity for drug discovery

1, 2007

Volltextzugriff (PDF)

Characterization of High-Order Diphtheria Toxin Oligomers

Biochemistry (Easton), 2000-12, Vol.39 (51), p.15901-15909

2000

Volltextzugriff (PDF)

Integrated Analysis of Global mRNA and Protein Expression Data in HEK293 Cells Overexpressing PRL-1: e72977

PloS one, 2013-09, Vol.8 (9)

2013

Volltextzugriff (PDF)

Characterization of diphtheria toxin high-order oligomerization and energetics

Steere, Boyd Allen

2001

Volltextzugriff (PDF)

Simulation of Absorption, Metabolism, and Bioavailability

Drug Bioavailability, 2003, p.420-443

2003

Volltextzugriff (PDF)

1 – 17 von 17

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(14)
Mit Volltextzugriff
(13)

Publikationsform

Sprache

Englisch
(17)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

S806 Mirikizumab-Induced Transcriptome Changes in Patient Biopsies at Week 12 Are Maintained Through Week 52 in Patients With Ulcerative Colitis

Integrated analysis of global mRNA and protein expression data in HEK293 cells overexpressing PRL-1

Generation and Characterization of Mirikizumab, a Humanized Monoclonal Antibody Targeting the p19 Subunit of IL-23

569 A TRANSCRIPTOME-DEPENDENT PROGNOSTIC MODEL OF RESPONSE IN PATIENTS WITH ULCERATIVE COLITIS

The Formation of Amphotericin B Ion Channels in Lipid Bilayers

Deconvolution of monocyte responses in inflammatory bowel disease reveals an IL-1 cytokine network that regulates IL-23 in genetic and acquired IL-10 resistance

Tu1467: MIRIKIZUMAB-INDUCED UPREGULATION OF COLONIC TRANSCRIPTS CORRELATES WITH IMPROVEMENTS IN STOOL FREQUENCY IN A PHASE 2 STUDY OF PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS

Sa1125 GENE EXPRESSION (GE) VALUES IN A PHASE 2 TRIAL OF MIRIKIZUMAB IN ULCERATIVE COLITIS (UC) CORRELATE BETTER WITH HISTOPATHOLOGY (HP) THAN ENDOSCOPY (EN) AND MAYO SCORES

Tu1854 MIRIKIZUMAB REGULATES GENES INVOLVED IN ANTI-TNF RESISTANCE AND ULCERATIVE COLITIS DISEASE ACTIVITY

Mirikizumab-Induced Transcriptome Changes in Ulcerative Colitis Patient Biopsies at Week 12 Are Maintained Through Week 52

Mirikizumab Regulates Genes Involved in Ulcerative Colitis Disease Activity and Anti-TNF Resistance: Results From a Phase 2 Study

Prediction of in vivo clearance and associated variability of CYP2C19 substrates by genotypes in populations utilizing a pharmacogenetics-based mechanistic model

Exploiting chemical diversity for drug discovery

Characterization of High-Order Diphtheria Toxin Oligomers

Integrated Analysis of Global mRNA and Protein Expression Data in HEK293 Cells Overexpressing PRL-1: e72977

Characterization of diphtheria toxin high-order oligomerization and energetics

Simulation of Absorption, Metabolism, and Bioavailability

Suchergebnisse filtern